Alternative fluid path for serially connectable drug modules

A modular drug delivery system with interconnected drug modules and a base tray addresses the challenges of needle stick injuries and drug wastage, enabling safe and efficient compounding of drug combinations in sterile and non-sterile environments, reducing errors and costs.

JP2024161385AActive Publication Date: 2024-11-19BRISTOL MYERS SQUIBB CO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024116660
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-08
Filing Date
2024-07-22
Publication Date
2024-11-19
Estimated Expiration
2040-11-09

AI Technical Summary

Technical Problem

Existing drug compounding systems for intravenous infusion face challenges such as high risk of needle stick injuries, medication errors, drug wastage, and complexity, especially when preparing synergistic combinations of drugs like anti-PD-1 checkpoint inhibitors and CTLA4 checkpoint inhibitors, which are costly and require sterile environments.

Method used

A modular drug delivery system comprising drug modules with vial chambers, cannulas, and sterile tubing for fluid pathways, allowing connection of multiple modules in series with automatic fluidic connections and pressure equalization, and a base tray for assembly without complex electronic error-proofing, enabling flexible configuration for use in controlled or uncontrolled environments.

Benefits of technology

The system reduces the risk of needle stick injuries, minimizes drug wastage, and simplifies the preparation of drug combinations, allowing for safe and efficient compounding of drugs in various settings, including patient homes, while maintaining sterility and reducing medication errors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161385000001_ABST
    Figure 2024161385000001_ABST
Patent Text Reader

Abstract

To provide modules useable in combinatorial drug delivery devices.SOLUTION: A module 10 may be provided with a vial spike 12 which is used to penetrate a vial septum 14 extending into an internal volume 16 of a drug vial 18 filled with liquid. A distal end 20 of the vial spike 12 may be sharp to facilitate penetration of the vial septum 14. The vial spike 12 must have sufficient length to fully penetrate the septum 14 when accessing the internal volume 16. The vial spike 12 includes two lumens that divide a module fluid device into a separate circuit, inflow path 22 and outflow path 24. When the vial spike 12 penetrates the septum, the inflow path 22 and outflow path 24 are connected to the internal volume 16 of the drug vial 18 through an opening formed at the distal end 20 of the vial spike 12.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The field of the invention is the compounding and preparation of liquid drugs, especially for intravenous infusion and direct injection into a patient. More specifically, the invention relates to solutions for fluid circuits and connections that would allow the use of the device for the preparation and compounding of combinations of two or more drugs. [Background technology]

[0002] It is common practice for the administration of drugs by intravenous infusion of drugs compounded in a pharmacy environment. Such drugs are usually supplied sterile in glass vials and may be supplied in the form of a solid or aqueous solution. If supplied in solid form, the drug needs to be prepared in a sterile aqueous diluent before being transferred to an infusion bag. Those skilled in the art will appreciate that such drug formulations typically include several excipients, e.g., buffers, pH adjusters, tonicity adjusters, stabilizers, etc. Typically, liquid drugs for intravenous infusion are compounded in an infusion bag in a pharmacy environment before being transferred for infusion to a patient. During compounding, compounding procedures are usually performed in a sterile compounding room (hood), since sterility of the drug needs to be maintained. Typically, a pharmacist or pharmacy technician (practitioner) prepares the drug according to an individual patient's prescription.

[0003] After ensuring that the hood is clear of all objects, the practitioner retrieves from the pharmacy inventory the vials of the medication required as per the prescription and verifies their identity and content. The verification process is assisted by a barcode scanner or other identification technology. The practitioner also retrieves from inventory all other necessary equipment required to safely prepare the medication for infusion, including the infusion bag itself, syringes, needles, transfer set, gloves, sharps disposal container, etc. Once all necessary equipment is gathered, the practitioner follows the procedure for preparation of the medication, which includes preparation of the solid medication by addition of diluents, sequentially removing the liquid medication from individual vials through transfer ports into an intravenous (IV) bag. Typically, this procedure is performed manually and uses multiple needles. The risk of needlestick injury to the practitioner increases with each needle required to perform the compounding of the medication. In the case of highly potent or toxic medications, such as cytotoxic drugs for chemotherapy, there is a significant risk of exposure for the practitioner.

[0004] To eliminate some of the risks associated with manual preparation, including exposure to hazardous drugs, and the risk of medication errors, drug compounding machines are known to those skilled in the art that automate many of the steps involved in drug preparation and compounding. Typically, such machines are complex electromechanical systems that implement sophisticated precision compounding mechanisms to accurately prepare liquid drugs. Aside from their cost, size, and complexity, many of the designs of such machines described in the art retrieve liquid drugs from stock storage and use only a portion of the drug in the container. Due to the need to maintain sterility, the unused drug liquid typically must be discarded, resulting in waste. This waste is a highly undesirable cost, as the cost of some drugs, especially biological drugs, is very high. When the wasted drugs are cytotoxic agents, their disposal creates significant environmental and safety hazards.

[0005] Recent advances in medicine, particularly in the treatment of cancer, have demonstrated that therapeutically beneficial effects can be achieved through the synergistic combination of two or more agents.

[0006] For example, recent clinical studies have shown that the combination of anti-PD-1 and CTLA4 checkpoint inhibitors can produce beneficial synergistic effects in some tumor types, leading to better clinical outcomes than can be achieved with the individual administration of each agent. Typically, such checkpoint inhibitors are monoclonal antibodies or immunoglobulin-type fragments derived from biotechnology. In some circumstances, it may be beneficial to combine such biologic agents with conventional chemotherapeutic agents, such as cytotoxic drugs.

[0007] Applicant hereby expressly disclaims all of the disclosures contained in U.S. Provisional Patent Application No. 62 / 670,266, filed May 11, 2018, PCT application no. PCT / US2019 / 031727, filed May 10, 2019, PCT application no. PCT / US2019 / 031762, filed May 10, 2019, and PCT application no. PCT / US2019 / 031791, filed May 10, 2019, all of which are incorporated herein by reference in their entirety. The combinatorial principles incorporated herein can address several challenges encountered in the preparation and compounding of drugs for intravenous infusion and can provide several advantages, including but not limited to, streamlining pharmacy procedures, reducing the risk of medication errors, containing and protecting practitioners from highly potent or toxic drugs, reducing the risk of needlestick injuries, reducing or eliminating drug waste, and avoiding the need for complex and expensive drug compounding machines. As a result of these advantages in embodiments, the present invention may further enable the preparation and compounding of drugs for intravenous (IV) infusion at locations away from pharmacies and by non-professionals, for example, by appropriately trained technicians or nurses in the patient's home. This feasibility is enhanced by the inherent transportability of the systems described herein. Summary of the Invention

[0008] According to the present invention, there is provided a plurality of drug modules, each defining a chamber for receiving a drug-filled vial. In embodiments, a spacer adapter may be provided or the vial retention dimensions may be altered to allow for different sized vials to be received. The module may further comprise a displaceable vial retaining device to allow access to the vial septum for sterilization, a cannula arranged to break the vial septum upon displacement of the vial retaining device, and a sterile tube defining a sterile fluid path from the cannula to inlet and outlet ports connecting with the sterile fluid path of an adjacent module. The modules may comprise male and female mating features such that any number of modules of the same design may be connected to each other in a "stack". Furthermore, the mating features and ports may be arranged such that the fluid connection between the modules is automatic when the modules are connected to each other in series through their respective mating features. Each module may be provided with a vent, including a vent terminated by a sterile particulate filter, to allow equalization of pressure within the vial during removal of liquid drug from the vial while preventing contaminants from entering the fluid path. The vents may be positioned such that when another module is mated adjacent to the vent side of the module, a seal is formed that closes the vent, thus allowing only the last module on the stack to vent to atmosphere.

[0009] In embodiments, the system may be equipped with a sterile air reservoir that may be used in place of atmospheric air. This feature allows the system to be used in less controlled environments, particularly in the patient's home environment.

[0010] A first module in the stack may be connected to the housing with a male port similar to that provided on the module. The housing may further comprise a sterile tube, and an eyelet tube may extend from the housing and terminate in a sterile hollow needle that may be used to break a sterile port in an infusion bag or other container and pump the liquid medicament into the bag or other container, or for direct administration of the medicament to a patient. Further pumping means may be provided such that when fully connected to the liquid medicament in multiple vials, the liquid medicament is pumped from each vial into the needle as one.

[0011] In embodiments, such pump means may be integral to the housing or may be external to the housing. The pump means may be sterile and form a component of the fluid pathway or may be of a non-contact type such as a peristaltic pump. Those skilled in the art will be familiar with a number of pump technologies suitable for use in pumping liquid medicaments in the manner described.

[0012] This delivery system embodiment provides additional flexibility to the system by allowing modules to be configured not only to connect to each other, but also to a common base tray, which allows a lower cost alternative to control module ordering and assembly without relying on more complex electronic error proofing systems that would be required if the modules were configured in a purely stackable architecture.

[0013] In the current embodiment of this system using a base tray, drug modules are inserted and mechanically secured within a common base tray provided, thereby fluidly connecting all inserted modules and delivering the contents of all modules. The base tray is comprised of several pre-positioned wells designed to accept the hinged cap geometry of the modules. Within each well are two check valve style fluid connection ports that mate with the input and output ports of the module vial spike plate. Fluidic connections are made between the base tray valves through the vial spike plate by sufficiently pushing the vial spike plate into the base tray valve. Internally, sterile tubing is used to fluidly connect the single check valves of adjacent wells to create a fluid circuit. This is completed when all wells of the base tray are filled with a particular module. The base tray includes an air filter and / or vent that terminates one end of the internal fluid circuit. The base tray fluid circuit flushes the drug product from the modules into a sterile main output line from the base tray. A one-way valve in the main output line prevents drug product from backflowing into the base tray.

[0014] Cooperating mechanical keying features on both the interior walls of the base tray wells and the exterior surface of the module's hinged cap create a poka-yoke mechanism that ensures that modules can only be inserted into intended wells of the base tray.

[0015] The main output line from the base tray is terminated by a sterile hollow needle that may be used to break a sterile port on an infusion bag or other container and pump the liquid medication into the container, or may be used for direct medication administration to a patient. Additionally, pumps may be provided such that when fully connected, the liquid medication in the vials is pumped as one collective output from each vial to a bag, container, or patient.

[0016] The pump may be integrated into the base tray or may be external to the base tray. The pump may be sterilized and form a component of the fluid pathway or may be of a non-contact type, such as a peristaltic pump. Those of skill in the art will be familiar with a number of pump technologies suitable for use in pumping liquid medications in the manner described.

[0017] Modifications can be made to the currently described systems to either the module or tray fluidic architecture, allowing modules to be configured in stackable arrangements or nested within a base tray. Configuration of these systems can be done on a case-by-case basis at the time of component assembly, within the supply chain, or by the user at the point of care. [Brief description of the drawings]

[0018] [Figure 1] Dual Circuit Module [Diagram 2] Connected dual circuit module [Diagram 3] Dual circuit module connected to pump [Figure 4] Dual circuit module with sterile air reservoir [Figure 5A] Configurable modular housing [Figure 5B] Configurable modular housing [Figure 6A] Removable Module Ports [Figure 6B] Removable Module Ports [Figure 7] Fluidic system of redundancy module [Figure 8] Horizontally loaded tray [Figure 9] Vial Float Valve [Figure 10] Foldable tray [Figure 11] Module Tray Adapter DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Various embodiments related to modules usable in a combination drug delivery device are described herein, including devices formed by connecting multiple modules in series (e.g., to form a stack) and devices formed by mounting the modules to a base tray or other support structure that fluidly connects the modules. Features of the embodiments can be combined in various combinations even if not explicitly disclosed. Descriptions of certain features, such as spike plates, interaction of the spike plate with an attached vial, vents, etc., are provided in terms of specific embodiments and are equally applicable to other embodiments, as will be understood by those skilled in the art.

[0020] In a first embodiment, as shown in FIGS. 1-4, the module 10 may be provided with a vial spike 12 that is used to penetrate a vial septum 14 that extends into an interior volume 16 of a liquid-filled drug vial 18. The distal end 20 of the vial spike 12 may be sharpened to facilitate the penetration of the vial septum 14. The vial spike 12 must be long enough to fully penetrate the septum 14 to access the interior volume 16. The vial spike 12 includes two lumens that divide the modular fluidic device into separate circuits, an inlet path 22 and an outlet path 24. By penetrating the septum, the inlet path 22 and the outlet path 24 are connected to the interior volume 16 of the drug vial 18 through openings formed at the distal end 20 of the vial spike 12.

[0021] The first fluid line 26 extends from the inlet path 22 to a first sealing port 28 located on the rear face 30 of the module 10 and connects the interior volume 16 of the drug vial 18 to the first sealing port 28. The first branch line 32 extends from the first fluid line 26 and connects with the first fluid line 26. The first branch line 32 includes an exposed tubing portion 34 that is exposed through the rear face 30 of the module 10. The exposed tubing portion 34 is preferably formed of a flexible tube. The second sealing port 36 is located on the rear face 30 of the module 10 and is connected by a second fluid line 42 to a third sealing port 38 located on the front face 40 of the module 10. The first branch line 32 extends to a second fluid line 42 and connects with the second fluid line 42. The fourth sealing port 44 is located on the front face 40 and is connected by a third fluid line 46 to the outlet path 24. Male pins 48 protrude from the front surface 40 and are configured to negatively engage the exposed tube portions 34 of similarly configured modules connected to the module 10, as described below. Ports or openings 50 may be formed in the back surface 30 that expose the exposed tube portions 34 and are configured to receive the male pins 48.

[0022] 2-4 show two modules 10 connected in series. As will be appreciated by those skilled in the art, any quantity of modules 10 may be utilized in a series connection. This allows the drug vials 18 of the modules 10 to contain different drugs (types, concentrations) that can be drawn in sequence and administered in combination. For purposes of illustration, the second module of the modules 10 is designated with the same reference numerals used for the drug module 10, but with the addition of the letter "a." As shown in FIG. 2, when the modules 10, 10a are connected, the first and second sealing ports 28, 36 on the rear surface 30 of the module 10 mate with the third and fourth sealing ports 38a, 44a of the second module 10a, forming a fluid connection between the primary and secondary circuits of the modules 10, 10a. The male pin 48a of the second module 10a is received in the port 50 and couples with the exposed tubing section 34, specifically by pinching and squeezing the exposed tubing section 34 closed on its flexible tubing, thereby connecting the primary and secondary inlet circuits of the series of modules 10, 10a up to the last module 10a. Specifically, a fluid chain is created between the modules 10, 10a, with the primary and secondary inlet circuits connected by being bridged by the first branch line 32a with the exposed tubing section 34a open for flow therethrough. This arrangement makes it possible to seal the first branch line 32 of the modules 10, except for the final module 10a, where flow is permitted to close the fluid circuit. Thus, a fluid path can begin at the third sealing port 38 of the first module 10, extend through the second fluid line 42 of each module 10, 10a, through the first branch line 32a of the last module 10a in the chain, and then through the drug vials 18, 18a of each module 10, 10a back to the fourth sealing port 44 on the front face 40 of the first module 10.

[0023] As will be appreciated by those skilled in the art, the fluid paths through the modules 10, 10a may be vented in any known manner. For example, one or both of the first sealing port 28 and the second sealing port 36 may be provided with an antibacterial filter that allows air flow but limits the passage of microorganisms. Additionally or alternatively, as shown in FIG. 4, one or more collapsible gas chambers 52 may be provided in connection with any of the fluid lines, including the first fluid line 26, the second fluid line 42, and the third fluid line 46, to accommodate, for example, a sterilizing gas (e.g., sterile air) or a stable gas (e.g., argon). Additionally, the fluid lines (first fluid line 26, first branch line 32, second fluid line 42, third fluid line 46) may be formed in whole or in part by tubing, including flexible tubing. Additionally or alternatively, the fluid lines (first fluid line 26, first branch line 32, second fluid line 42, third fluid line 46) may be formed in whole or in part by passages formed in the module 10. As noted above, exposed tube portion 34 is preferably formed from flexible tubing so that it is pinchable in response to compressive engagement by male pins 48 of adjacent connected modules 10 .

[0024] Additionally, the modules 10 may be connected in any known manner, including, for example, cooperating fastening elements on opposing faces. Interengagement of the ports 50 and male pins 48 between adjacent modules 10 may be utilized to form connections therebetween.

[0025] To form a drug delivery device 54 with all modules 10 connected in series with fluid connections, a pump module 56 can be positioned at the front 40 of the first module 10 in the chain and coupled with the third sealing port 38 and the fourth sealing port 44 as the inlet and outlet ports of the module chain. The pump module 56 includes a first inlet sealing port 58 configured to interengage with the fourth sealing port 44 of the first module 10, a second inlet sealing port 60 configured to interengage with the third sealing port 38 of the first module 10, a first outlet port 62, and a pump 64. An outlet passage 66 is defined between the first inlet sealing port 58 and the first outlet port 62, and the pump 64 is configured to draw liquid drug into the outlet passage 66 and push the drawn liquid drug out of the first outlet port 62 via the fourth sealing port 44 / first inlet sealing port 58 interface. The outlet passage 66 may be a closed passage in which the pump 64 acts peristaltically on the outlet passage 66 to maintain the sterility of the liquid medication passing therethrough.

[0026] A vent passageway 68 may be provided in connection with the second inlet sealing port 60 to provide vent to the fluid circuitry of the module 10, 10a via the third sealing port 38. The vent passageway 68 may terminate in a one-way air vent 70. As shown in FIG. 4, the one-way air vent 70 may be replaced with one or more collapsible gas chambers 52, for example, containing a sterile gas (e.g., sterile air) or a stable gas (e.g., argon). This allows the device 54 to be utilized in home care environments where access to a controlled environment with air filtration may not be available.

[0027] The drug delivery device 54 may be utilized in a variety of applications. The drug delivery device 54 is particularly suited for home use and is self-contained for providing combination drug therapy. The first exit port 62 is connected to a flexible tube 72 and connected to a drug delivery needle (not shown) for direct drug administration to a patient or to a container, such as an IV bag 74, in which the drug may be collected for subsequent administration. In use, as shown in Figures 3 and 4, the pump 64 may be actuated to draw liquid drug from the drug vial 18, 18a and deliver it through the first exit port 62, and venting may be provided by one or more of the collapsible gas chamber 52 and / or vent passages 68.

[0028] Alternative embodiments of modular fluidic devices may be desirable to use configurable modules that can be serially connected together or configured to mount to other support structures such as base trays or "po-po-po" trays. As shown in Figures 5A and 5B, a cross section of a modular body housing 100 is shown with cutouts 102 for securing different components of a fluid path subassembly. The top surface 104 of the housing 100 has a cutout 102a for a spike plate 106 formed to access the drug from a drug vial in a similar manner as described above, while the front surface 108 and back surface 110 have cutouts 102b, 102c, respectively, for securing a sealing port 112, and the bottom surface 114 has cutouts 102d, 102e for two sealing ports 112. The spike plate 106 is a two lumen spike plate, with each lumen continuing to a portion of a flexible tube 116 that terminates in a sealing port 112. At the time of module assembly, the spike plate 106 is assembled into the top cutout 102a and sealing ports 112 can be positioned as inlet and outlet fluid paths by being located on either the opposing front 108 and back 110 of the module housing 100 for a serial stack configuration (FIG. 5A), or on the bottom 114 (FIG. 5B) to allow interaction of the module 100 with a base tray or other support structure.

[0029] Further embodiments of this concept may include configuring modules for stackable or tray configuration at the point of care. By using configurable subassemblies with flexible tubing, the fluid pathways may be permanently contained within the solid module body 200 during assembly, with the input and output sealing ports 202, 204 held within a port housing 206 attached to the module body 200 by a hinge. The hinge of the port housing 206 to the module body 200 allows the input and output sealing ports 202, 204 of the fluid pathways to be oriented for either base tray mounting as shown in FIG. 6A or for serial connection as shown in FIG. 6B.

[0030] The alternative modular fluidic system solution utilizes redundant fluidic systems for use in either configuration, closing unused circuits when in use, allowing for the use of modules in alternative base tray mountings and serial connections. As shown in FIG. 7, each module 300 includes a vial spike 302 that is used to penetrate the vial septum to extend into the interior volume of a liquid-filled drug vial and access the drug therein. The vial spike 302 must be long enough to fully penetrate the septum to access the interior volume. The vial spike 302 includes two lumens that divide the modular fluidic system into separate circuits, an inlet path 304, and an outlet path 306. With the vial spike penetrating the septum, the inlet path 304 and the outlet path 306 connect with the interior volume of the drug vial through openings formed at the distal end 308 of the vial spike 302 in a manner similar to that described above in connection with the vial spike 12.

[0031] A first fluid line 310 extends from the inlet path 304 to a first sealing port 312 located on a back surface 314 of the module 300 and connects the interior volume of the drug vial with the first sealing port 312. The first fluid line 310 includes a first exposed tubing portion 316 that is exposed through a bottom surface 318 of the module 300. A first branch line 320 extends from the first fluid line 310 and connects with the first fluid line 310. The first branch line 320 includes a second exposed tubing portion 322 that is exposed through the back surface 314 and extends to a second sealing port 324. A third sealing port 326 is located on a front surface 328 of the module 10. A second fluid line 330 connects the outlet path 306 to the third sealing port 326. A fourth sealing port 332 is disposed in the bottom surface 318, from which a second branch line 334 extends to the second fluid line 330, connecting the fourth sealing port 332 and the second branch line 334. A first male pin 336 protrudes from the front surface 328 and is configured to negatively engage a second exposed tubing portion 322 of a similarly formed module connected to the module 300, as described below. A first port or opening 338 may be formed in the back surface 314, exposing the second exposed tubing portion 322 and configured to receive the first male pin 336. As shown, with two of the modules 300, 300a connected in series, the first male pin 336a of the second module 300a is received in the first port 338 of the adjacent module 300 to negatively block the second exposed tubing portion 322. In this manner, a continuous flow path spanning all of the drug vials in the module 300 can be formed outside the second sealing port 324 and the fourth sealing port 332 .

[0032] The module 300 may be utilized with a base tray 340 from which a second male pin 342 configured to positively engage the first exposed tube portion 316 when the module 300 is directly connected. A second port or opening 344 may be formed in a bottom surface 318 of the module 300 to expose the first exposed tube portion 316 and to receive the second male pin 342. The base tray 340 may include a nest 346 configured to insertably receive the module 300. When the module 300 is received in the nest 346, a first exhaust seal port 348 and a second exhaust seal port 350 in a base 352 of the nest 346 interlock with the second seal port 324 and the fourth seal port 332 of the module 300, respectively, and the second male pin 342 is received in the second port 344 to positively block the first exposed tube portion 316. In this manner, a flow path may be created to and from the base tray 340 that bypasses the first sealing port 312 and the third sealing port 326 .

[0033] To facilitate the formation of the desired fluid circuits, one or more one-way check valves 354 may be provided to restrict flow in one direction, thereby blocking unused fluid lines. For example, one of the check valves 354 may be positioned along the second branch line 334 to allow flow only from the fourth sealing port 332, thereby restricting unwanted flow to the fourth sealing port 332 when the modules 300 are connected in series. Additionally or alternatively, one of the check valves 354 may be positioned along the second fluid line 330 to allow flow only from the third sealing port 326, thereby restricting unwanted flow to the third sealing port 326 when the modules 300 are attached to the base tray 340.

[0034] As will be appreciated by those skilled in the art, the fluid pathways through the module 300 may be vented in any known manner. For example, one or both of the first sealing port 312 and the second sealing port 324 may include an antimicrobial filter that allows air flow therethrough but limits the passage of microorganisms therethrough. Additionally or alternatively, the fluid lines (first fluid line 310, first branch line 320, second fluid line 330, second branch line 334) may be formed in whole or in part by passages formed in the module 300. The first exposed tube portion 316 and the second exposed tube portion 322 are preferably each formed by flexible tubing such that they are pinchable in response to push-in engagement by the first male pin 336 and the second male pin 342, respectively.

[0035] Additionally, the modules 300 may be connected in any known manner, including, for example, cooperating fastening elements on opposing faces. Interengagement of the first male pins 336 and first ports 338 between adjacent modules 300 may be utilized to form a connection therebetween.

[0036] In an alternative fluidic device embodiment, the modules can be coupled to the fluidic device of the base tray through modifications to the base tray in forming the drug delivery device. As shown in FIG. 8, the wells 402 of the base tray 400 can be configured horizontally, allowing for lateral loading of the modules 404 to the tray 400. Because the modules 404 are not connected in series, only one fluid coupling is required to connect each of the exhaust ports 406 of the modules 404 to the corresponding inlet ports 408 of the tray 400. The inlet ports 408 of the tray 400 can be connected to a common exhaust 410, for example, by being manifolded within the tray 400. The common exhaust 410 can exhaust to a flexible tube 412 for delivery to a container such as a needle 413 or an IV bag. Negative pressure can be applied to the common exhaust 410, for example, via the flexible tube 412. For example, a peristaltic pump can be applied to the flexible tube 412 to deliver the output to an IV bag.

[0037] The modules 404 may be vented to the atmosphere, so that as fluid is drawn from the modules 404, air may be automatically drawn into each vial to replace the fluid during transfer. As the modules 404 begin to empty, their fluid paths may be closed to prevent drawing straight from the atmosphere. As a non-limiting example, the drug vials 418 of the modules 404 may be modified to each include a float valve 414, as shown in FIG. 9. The float valve 414 may be a piece of pierceable low density material held inside each drug vial 418 that floats on top of the liquid drug product 420. As medication 420 is pulled from the bottom of vial 418 through vial spike 422, the level of medication 420 drops, and eventually, when vial 418 is empty and float 414 is all that remains in the valve, the vacuum from spike 422 pulls float 414 onto spike 422, blocking spike 424, and specifically the inlet and outlet lumens, from the vial and any vent paths.

[0038] Additionally, the wells 402 may each be formed with a cross-section that matches the cross-section of a corresponding fixed portion 424 that protrudes from the bottom 426 of one of the modules 404. This provides a sliding guide for the outlet port 406 to mate with the inlet port 408. Additionally, the wells 402 may have a non-rectangular cross-section, e.g., a trapezoidal cross-section, with the fixed portion 424 having a matching cross-section, with interengagement therebetween that limits removal of the module 404 from the well 402. Additionally, the quantity of wells 402 may be varied with the corresponding quantity of fixed portions 424. This allows for controlled sequential placement of the modules 404 in a desired order. The cross-section of the wells 402 / fixed portions 424 may also and / or instead be varied to specify a desired order of the modules 404.

[0039] A further embodiment in which the placement of the current modules can be managed via control of the tray 500 is shown in FIG. 10. The tray 500 consists of individual po-ka-yoke platforms 502 joined together by telescoping rails 504. The platforms 502 have keying features on their top surfaces that correspond to features on the underside of the modules 506. During assembly, the modules 506 are attached to the correct matching platforms 502 of the tray 500. When the user presses the ends of the tray 500 together, the tray 500 can collapse along the telescoping rails 504, allowing the modules 506 to connect to each other, creating a stack of fluidly connected modules 506. A tubing set 508 can then be placed in the front module 506 to transfer the contents of the module 506 to a needle or container, such as an IV bag.

[0040] A further solution that allows modules to both mate and be connected in series with a base tray, without changing either design, can be realized by using an adapter component 600 that assembles around a module 602 and changes the location of the fluid inlet and outlet ports, as shown in FIG. 11. The module 602 includes a spike plate 604 with an inlet path 606 and an outlet path 608 formed in a manner similar to the spike plate 12 described above. The module 602 further includes a first sealing port 610 connected to the inlet path 606 by a first fluid line 612 and a second sealing port 614 connected to the outlet path 608 by a second fluid line 616. The first sealing port 610 is located along a rear surface 618 of the module 602, while the second sealing port 614 is located along a front surface 620 of the module 602. In this configuration, the first sealing port 610 and the second sealing port 614 are located in opposite directions on opposite faces of the module 602. This configuration allows the module 604 to be connected in series with similarly formed modules 604 in forming a combination drug delivery device.

[0041] The adapter 600 is made from multiple parts 600a, 600b, possibly including two halves representing an input side and an output side. The adapter 600 can be attached to the module 602 by mating the parts 600a, 600b. For example, the halves 600a, 600b of the adapter 600 can be placed around the module 602 and pressed together to permanently mate with a plastic snap mechanism around the module 602.

[0042] The adapter 600 includes a first interior port 622 and a second interior port 624. When the adapter 600 is attached to the module 602, the first interior port 622 is positioned to align with the first sealing port 610 and the second interior port 624 is positioned to align with the second sealing port 614. A first secondary fluid line 626 connects the first interior port 622 to a first exhaust port 628. A second secondary fluid line 630 connects the second interior port 632 to a second exhaust port 634. The first exhaust port 628 and the second exhaust port 634 are positioned on a common face 636 of the adapter 600 and face a common direction transverse to the orientation direction of the first sealing port 610 and the second sealing port 614. This arrangement allows the adapter 600 to fluidly connect the module 602 to a base tray. Thus, the modules 602 can be connected in series without the adapter 600, and can be used with the base tray with the adapter 600.

[0043] The components of the adapter 600 may be split between the parts 600a, 600b, including being split evenly. For example, the first internal port 622, the first secondary fluid line 626, and the first exhaust port 628 may be located in one of the parts 600a, and the second internal port 624, the second secondary fluid line 630, and the second exhaust port 634 may be located in the second part 600b. This allows the fluid paths to be fully contained in each of the parts 600a, 600b without interrupting them. Additionally, one or more mating parts may be formed on the adapter 600 and the module 602 to strengthen the connection therebetween. For example, one or more protrusions 638 may be formed on the adapter 600 and / or the module 602 and are formed to be nested into corresponding recesses 640 formed in the adapter 600 and / or the module 602.

Claims

1. 1. A module for use in a combination drug delivery device, said module configured to receive a drug vial sealed by a septum, said module comprising: a vial spike configured to pierce the septum of the drug vial contained by the module, the drug vial including an inlet path and a separate outlet path; A first sealing port; a first fluid line connecting the inlet path to the first seal port; a first branch line extending from and connecting with the first fluid line, the first branch line including an exposed pipe portion; A second sealing port; A third sealing port; a second fluid line connecting the second sealing port with the third sealing port, the first branch line extending into and connecting with the second fluid line; A fourth sealing port; and a third fluid line connecting the discharge path to the fourth seal port; a male pin connected directly to said module and configured for positive engagement with said exposed tube portion of a similarly configured module; A module comprising:

2. The module of claim 1 , further comprising at least one collapsible gas chamber connecting with one or more of the first fluid line, the second fluid line, and the third fluid line.

3. 1. A combination drug delivery device comprising: a plurality of modules formed in accordance with claim 1, said plurality of modules being connected in series to form said modular combination, a first one of said modules defining an end of said combination; a pump module connected to the first module, the pump module including a first inlet sealing port mating with the fourth sealing port of the first module, a second inlet sealing port mating with the third sealing port of the first module, a first exhaust port, and a pump, an exhaust passageway defined between the first inlet sealing port and the first exhaust port, the pump configured to draw liquid medicament into the exhaust passageway and to push the drawn liquid medicament out of the first exhaust port. Combination drug delivery device.

4. 4. The combination drug delivery device of claim 3, wherein the pump module includes a vent passageway connecting with the second inlet sealing port.

5. 4. The combination medication delivery device of claim 3, wherein the pump module includes at least one collapsible gas chamber in communication with the second inlet sealing port.

6. 1. A module for use in a combination drug delivery device, said module configured to receive a drug vial sealed by a septum, said module comprising: a vial spike configured to pierce the septum of the drug vial contained by the module, the vial spike including an inlet path and a separate outlet path; A first sealing port; a first fluid line including a first exposed pipe portion connecting the inlet path with the first sealing port; A second sealing port; a first branch line extending from and connecting with the first fluid line, the first branch line extending to the second sealing port, the first branch line including a second exposed pipe portion; A third sealing port; a second fluid line connecting the discharge path to the third sealing port; A fourth sealing port; and a second branch line extending from and connecting with the second fluid line, the second branch line extending to the fourth sealing port; a male pin configured to positively engage the second exposed tube portion of a similarly configured module directly connected to the module; A module comprising:

7. A module according to claim 6; a base tray including a second male pin configured to positively engage the first exposed tube portion when the module is directly connected to the base tray; A combination that includes:

8. 1. A module for use in a combination drug delivery device, said module configured to receive a drug vial sealed by a septum, said module comprising: a vial spike configured to pierce the septum of the drug vial contained by the module, the vial spike including an inlet path and a separate outlet path; A first sealing port; a first fluid line connecting the inlet path to the first seal port; A second sealing port; a second fluid line connecting the discharge path to the second sealing port; the first and second sealing ports are located on opposite sides of the module and face in opposite directions; A module, An adapter attachable to the module, the adapter comprising: A first internal port; A second internal port; and A first exhaust port; a first secondary fluid line connecting the first internal port with the first exhaust port; A second exhaust port; a second secondary fluid line connecting the second internal port with the second exhaust port; an adapter including: Equipped with the first exhaust port and the second exhaust port are disposed on a common side of the adapter and face the same common direction; when the adapter is attached to the module, the first internal port is aligned with the first sealing port, the second internal port is aligned with the second sealing port, and the common direction of the first exhaust port and the second exhaust port is transverse to a direction of the first sealing port and the second sealing port. combination.

9. The combination of claim 8 , wherein the adapter is formed from multiple pieces.

10. The combination of claim 9 , wherein the adapter is attached to the module by coupling the plurality of parts together.

11. 10. The combination of claim 9, wherein a first part of the plurality of parts includes the first internal port, the first secondary fluid line, and the first exhaust port, and a second part of the plurality of parts includes the second internal port, the second secondary fluid line, and the second exhaust port.

12. a base tray having a plurality of inlet ports connected to a common outlet and at least one well formed therein extending to each of the inlet ports; a plurality of modules, each of the plurality of modules including a drug vial, an outlet port for releasing a drug from the drug vial, and at least one protruding fixing portion, each of the modules corresponding to one of the inlet ports; Equipped with in each of said modules, the number of fixed portions corresponds to the number of said wells associated with a corresponding inlet port; the modules are coupled with the corresponding inlet ports when the respective at least one fixed portion is received in the corresponding at least one well; Combination drug delivery device.

13. 13. The combination drug delivery device of claim 12, wherein in each of the modules, the respective at least one fixed portion has a cross-section that mates with the corresponding at least one well.

Citation Information

Patent Citations

  • drug volumetric device

    JP2003527933A

  • Connectable devices and device assemblies for delivering liquid medicaments

    JP2009529995A

  • Multi-container fluid transfer and delivery device

    JP2013525004A

  • Storage device for single or multiple containers

    JP2018519141A